Search research articles
Contact Us
Filters
Showing results (21-30 of 45) with videos related to
Page
of 5
Sort By:
Clinical Pharmacology in Drug Development
|
March 9, 2026
Results of a Phase 1 Study Assessing the Effect of CIN-102, a Novel Formulation of the Dopamine Receptor Antagonist Domperidone Designed to Treat Gastroparesis, on Cardiac Repolarization in Healthy Volunteers
Mary Bond, Brian Murphy, Brendan Doran, et al.
Clinical Pharmacology in Drug Development
|
August 31, 2019
Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study
Marie T Borin, Chris N Barnes, Borje Darpo, et al.
Orphanet Journal of Rare Diseases
|
October 28, 2020
The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects
Markus S Mueller, Patricia N Sidharta, Christine Voors-Pette, et al.
Antimicrobial Agents and Chemotherapy
|
January 30, 2026
Cardiodynamic evaluation of sorfequiline (TBAJ-876): results from a first-in-human study
Borje Darpo, Jerry Nedelman, Rebecca Bruning-Barry, et al.
Journal of Clinical Pharmacology
|
July 6, 2026
How to Replace the TQT Study-The Use of Concentration-QTc Modeling to Exclude a Small Effect of a Novel Drug on QT Interval: Historical Perspective and Implementation
Borje Darpo, Georg Ferber, Seth C Hopkins, et al.
Clinical Pharmacology in Drug Development
|
January 19, 2021
Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D<sub>2</sub> /D<sub>3</sub> Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants
Roger L Whiting, Borje Darpo, Chunlin Chen, et al.
Journal of Clinical Pharmacology
|
January 14, 2026
No QTcF Prolongation with Sepiapterin: Results From a Thorough QT Study in Healthy Subjects at Therapeutic and Supratherapeutic Doses
Lan Gao, Hongqi Xue, Borje Darpo, et al.
Clinical Pharmacology in Drug Development
|
March 23, 2026
Thorough QT Study on the Effect of Therapeutic and Supratherapeutic Dosing of Givinostat in Healthy Volunteers
Eugenio Mercuri, Barry Byrne, Tracey Willis, et al.
Clinical Pharmacology in Drug Development
|
July 17, 2020
Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors
Ken Ogasawara, Christine Xu, Jian Yin, et al.
Alzheimer Disease and Associated Disorders
|
May 27, 2022
E2027 Cardiac Safety Evaluation With Concentration-Response Modeling of ECG Data to Inform Dose Selection in Studies in Patients With Dementia With Lewy Bodies
Ishani S Landry, Peter Boyd, Jagadeesh Aluri, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 45) with videos related to
Sort By:
Page
of 5
Clinical Pharmacology in Drug Development
|
March 9, 2026
Results of a Phase 1 Study Assessing the Effect of CIN-102, a Novel Formulation of the Dopamine Receptor Antagonist Domperidone Designed to Treat Gastroparesis, on Cardiac Repolarization in Healthy Volunteers
Mary Bond, Brian Murphy, Brendan Doran, et al.
Clinical Pharmacology in Drug Development
|
August 31, 2019
Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study
Marie T Borin, Chris N Barnes, Borje Darpo, et al.
Orphanet Journal of Rare Diseases
|
October 28, 2020
The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects
Markus S Mueller, Patricia N Sidharta, Christine Voors-Pette, et al.
Antimicrobial Agents and Chemotherapy
|
January 30, 2026
Cardiodynamic evaluation of sorfequiline (TBAJ-876): results from a first-in-human study
Borje Darpo, Jerry Nedelman, Rebecca Bruning-Barry, et al.
Journal of Clinical Pharmacology
|
July 6, 2026
How to Replace the TQT Study-The Use of Concentration-QTc Modeling to Exclude a Small Effect of a Novel Drug on QT Interval: Historical Perspective and Implementation
Borje Darpo, Georg Ferber, Seth C Hopkins, et al.
Clinical Pharmacology in Drug Development
|
January 19, 2021
Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D<sub>2</sub> /D<sub>3</sub> Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants
Roger L Whiting, Borje Darpo, Chunlin Chen, et al.
Journal of Clinical Pharmacology
|
January 14, 2026
No QTcF Prolongation with Sepiapterin: Results From a Thorough QT Study in Healthy Subjects at Therapeutic and Supratherapeutic Doses
Lan Gao, Hongqi Xue, Borje Darpo, et al.
Clinical Pharmacology in Drug Development
|
March 23, 2026
Thorough QT Study on the Effect of Therapeutic and Supratherapeutic Dosing of Givinostat in Healthy Volunteers
Eugenio Mercuri, Barry Byrne, Tracey Willis, et al.
Clinical Pharmacology in Drug Development
|
July 17, 2020
Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors
Ken Ogasawara, Christine Xu, Jian Yin, et al.
Alzheimer Disease and Associated Disorders
|
May 27, 2022
E2027 Cardiac Safety Evaluation With Concentration-Response Modeling of ECG Data to Inform Dose Selection in Studies in Patients With Dementia With Lewy Bodies
Ishani S Landry, Peter Boyd, Jagadeesh Aluri, et al.
Page
of 5